Negma group has converted 380 convertible bonds in Oxurion resulting in EUR 950,000 capital increase. This is part of Negma Group’s capital commitment of EUR 30 million1 which will allow Oxurion to focus on the advancement of its new and differentiated drug for the back of the eye candidate targeting potential market opportunities greater than USD 5 billion kunas.
Leuven, BelgiumLGIUM, Boston, MA, USA – December 12, 2022 – 08.00 ANDM CET – In accordance with Article 15 of the Belgian Law of May 2, 2007 on the publication of major holdings in issuers whose shares are admitted to trading on a regulated market and in connection with various provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the information below, following the issuance of 99,789,915 new ordinary shares on December 9, 2022, in the total amount of EUR 950,000, as a result of the conversion of 380 convertible bonds of class B, in accordance with the capital commitment concluded with Negma Group.
Following the completion of the capital increase by conversion of convertible bonds, the total number of shares issued by Oxurion is 411,071,559 ordinary shares outstanding with voting rights (compared to 311,281,644 ordinary shares outstanding previously). This number will be used as the denominator to calculate the share percentages.
Oxurion therefore publishes the following updated information:
|
75,856,161.32 |
|
|
411,071,559 |
|
|
411,071,559 |
|
|
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing the next generation of standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in work-age people , as well as other states. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its new therapeutic agent for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor that is being developed as a potential new standard of care for up to 50% of DME patients who show a suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations and, accordingly, involve and are affected by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Additional information about the risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s annual report. This press release does not constitute an offer or solicitation to sell or buy the securities or assets of Oxurion in any jurisdiction. No Oxurion securities may be offered or sold within the United States without registration under the US Securities Act of 1933, as amended, or pursuant to an exemption therefrom, and in compliance with all applicable US state laws on securities.
For additional information, please contact:
1 Press release Oxurion, 06/04/2021 and Press release Oxurion, 02/09/2022
Side dish
